RELEBACTAM SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H19N4O6S.Na
Molecular Weight	370.357
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]S(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O

InChI

InChIKey=MMUZXOWPDRLGBD-UXQCFNEQSA-M

InChI=1S/C12H20N4O6S.Na/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21;/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21);/q;+1/p-1/t9-,10+;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24433862 | https://pubchem.ncbi.nlm.nih.gov/compound/Relebactam-sodium | https://clinicaltrials.gov/ct2/show/NCT03583333 | https://clinicaltrials.gov/ct2/show/NCT03969901

Relebactum sodium (MK-7655) is a piperidine analog 3 that inhibits class A and C β-lactamases (in vitro). It is being investigated for use in treatment of infectious diseases, such as treatment of gram-negative bacterial infections. Its potential as an alternative to existing medicines in the treatment of drug-resistant bacterial infections is being studied. Clinical trials have been conducted and are still ongoing to evaluate the efficacy and safety of relebactum sodium in treatment of intra-abdominal infections, urinary tract infections (such as pyelonephritis), hospital-acquired and ventilator-associated bacterial pneumonias, and gram-negative bacterial infections.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Class A carbapenemase 3 Target ID: 1.6834582E7 Gene Symbol: blaKPC-2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26498989	Inhibitor 8297		210.0 nM [IC50]
beta-lactamase 3 Target ID: 878149.0 Gene Symbol: ampC Sources: https://www.ncbi.nlm.nih.gov/pubmed/26498989	Inhibitor 8297		410.0 nM [IC50]

C_max

Value	Dose	Co-administered	Analyte	Population
64 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	250 mg 4 times / day multiple, intravenous dose: 250 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: IMIPENEM	IMIPENEM	RELEBACTAM ANHYDROUS plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
427.3 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	250 mg 4 times / day multiple, intravenous dose: 250 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: IMIPENEM	IMIPENEM	RELEBACTAM ANHYDROUS plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
396 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	1150 mg single, intravenous dose: 1150 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.97 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	250 mg 4 times / day multiple, intravenous dose: 250 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: IMIPENEM	IMIPENEM	RELEBACTAM ANHYDROUS plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	1150 mg single, intravenous dose: 1150 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29914955/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:		RELEBACTAM ANHYDROUS plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
78% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	250 mg 4 times / day multiple, intravenous dose: 250 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: IMIPENEM	IMIPENEM	RELEBACTAM ANHYDROUS plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 4 times / day multiple, intravenous Recommended Dose: 250 mg, 4 times / day Route: intravenous Route: multiple Dose: 250 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://pubmed.ncbi.nlm.nih.gov/29311084/	healthy, 24 to 42 years n = 17 Health Status: healthy Age Group: 24 to 42 years Sex: M+F Population Size: 17 Sources: https://pubmed.ncbi.nlm.nih.gov/29311084/	Disc. AE: Diarrhea, Nausea... Other AEs: Fatigue, Blood creatinine increased... AEs leading to discontinuation/dose reduction: Diarrhea (grade 1, 5.9%) Nausea (grade 2, 5.9%) Vomiting (grade 2, 5.9%) Other AEs: Fatigue (grade 1, 5.9%) Blood creatinine increased (grade 1, 5.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/29311084/
125 mg 4 times / day multiple, intravenous Dose: 125 mg, 4 times / day Route: intravenous Route: multiple Dose: 125 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://pubmed.ncbi.nlm.nih.gov/27503659/	unhealthy, mean age 49.7 years n = 87 Health Status: unhealthy Condition: Complicated Intra-Abdominal Infection Age Group: mean age 49.7 years Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/27503659/	Disc. AE: Decreased creatinine clearance... Other AEs: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Decreased creatinine clearance (1.1%) Other AEs: Diarrhea (>5) Nausea (>5) Vomiting (>5) Sources: https://pubmed.ncbi.nlm.nih.gov/27503659/
250 mg 4 times / day multiple, intravenous Recommended Dose: 250 mg, 4 times / day Route: intravenous Route: multiple Dose: 250 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	unhealthy, mean age 56.4 years and 49.1 years n = 216 Health Status: unhealthy Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection Age Group: mean age 56.4 years and 49.1 years Sex: M+F Population Size: 216 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	Other AEs: Anemia, Diarrhea... Other AEs: Anemia (1%) Diarrhea (6%) Nausea (6%) Vomiting (3%) Infusion site phlebitis (2%) Pyrexia (2%) Alanine aminotransferase increased (3%) Aspartate aminotransferase increased (3%) Lipase increased (1%) Blood creatinine increased (<1%) Headache (4%) Central nervous system disorder NOS (1%) Hypertension (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf
625 mg 4 times / day multiple, intravenous MTD Dose: 625 mg, 4 times / day Route: intravenous Route: multiple Dose: 625 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	healthy, median age 27 years n = 6 Health Status: healthy Age Group: median age 27 years Sex: M Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	Other AEs: Upper abdominal pain, Diarrhea... Other AEs: Upper abdominal pain (grade 1-2, 16.7%) Diarrhea (grade 1-2, 16.7%) Infusion site erythema (grade 1-2, 50%) Infusion site pain (grade 1-2, 50%) Infusion site pruritus (grade 1-2, 16.7%) Infusion site swelling (grade 1-2, 16.7%) Dizziness (grade 1-2, 16.7%) Headache (grade 1-2, 16.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/
1150 mg 1 times / day single, intravenous MTD\|Highest studied dose Dose: 1150 mg, 1 times / day Route: intravenous Route: single Dose: 1150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	healthy, median age 28.5 years n = 6 Health Status: healthy Age Group: median age 28.5 years Sex: M Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	Other AEs: Feeling of body temperature change... Other AEs: Feeling of body temperature change (grade 1-2, 16.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/
500 mg 4 times / day multiple, intravenous MTD Dose: 500 mg, 4 times / day Route: intravenous Route: multiple Dose: 500 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	healthy, median age 53.3 n = 24 Health Status: healthy Age Group: median age 53.3 Sex: M Population Size: 24 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/	Other AEs: Diarrhea, ALT increased... Other AEs: Diarrhea (grade 1-2, 8.3%) ALT increased (grade 1-2, 4.2%) Discoloration tongue (grade 1-2, 33.3%) Discoloration tooth (grade 1-2, 4.2%) Asthenia (grade 1-2, 4.2%) Feeling hot (grade 1-2, 4.2%) Feeling of body temperature change (grade 1-2, 4.2%) Infusion site erythema (grade 1-2, 37.5%) Infusion site pain (grade 1-2, 25%) Infusion site swelling (grade 1-2, 20.8%) AST increased (grade 1-2, 4.2%) Decreased appetite (grade 1-2, 4.2%) Arthralgia (grade 1-2, 4.2%) Muscle twitching (grade 1-2, 4.2%) Myalgia (grade 1-2, 4.2%) Headache (grade 1-2, 12.5%) Rash (grade 1-2, 4.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/29914955/
125 mg 4 times / day multiple, intravenous Dose: 125 mg, 4 times / day Route: intravenous Route: multiple Dose: 125 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	unhealthy, median age 58 years n = 99 Health Status: unhealthy Condition: complicated urinary tract infections Age Group: median age 58 years Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	Other AEs: Thrombocytosis, Abdominal pain... Other AEs: Thrombocytosis (1%) Abdominal pain (2%) Diarrhoea (2%) Nausea (6.1%) Bacteriuria (2%) ALT increased (1%) AST increased (2%) Bacterial test positive (1%) Blood creatinine increased (1%) White blood cells urine positive (1%) Dysgeusia (2%) Headache (3%) Hypertension (2%) Transaminases increased (1%) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/
250 mg 4 times / day multiple, intravenous Dose: 250 mg, 4 times / day Route: intravenous Route: multiple Dose: 250 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	unhealthy, median age 58 years n = 99 Health Status: unhealthy Condition: complicated urinary tract infections Age Group: median age 58 years Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	Disc. AE: Diarrhoea, Rash... Other AEs: Thrombocytosis, Diarrhoea... AEs leading to discontinuation/dose reduction: Diarrhoea (1%) Rash (1%) Other AEs: Thrombocytosis (2%) Diarrhoea (5.1%) Nausea (4%) Pyrexia (2%) Bacteriuria (1%) Influenza (2%) ALT increased (2%) AST increased (1%) Bacterial test positive (1%) Protein urine present (1%) Red blood cells urine positive (1%) White blood cells urine positive (1%) Headache (7.1%) Hypertension (3%) Transaminases increased (1%) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/
125 mg 4 times / day multiple, intravenous Dose: 125 mg, 4 times / day Route: intravenous Route: multiple Dose: 125 mg, 4 times / day Co-administed with:: imipenem(500 mg; IV; 4 per day) cilastatin(500 mg; IV; 4 per day) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	unhealthy, median age 60 years n = 99 Health Status: unhealthy Condition: complicated urinary tract infections Age Group: median age 60 years Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (1%) Sources: https://pubmed.ncbi.nlm.nih.gov/28575389/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767		inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 P-gp 1461 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OCT2 647 MATE1 306 MATE2 263 BCRP 699 BSEP 402 Nav1.5 97	OAT3 339 OAT4 78 OAT1 326 OCT2 355 P-gp 1537 BCRP 561 MRP2 205 MRP4 77 MATE1 135 MATE2 96	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
MATE1 308	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
MATE2 263	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no [IC50 >300 uM]
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=77 Page: 77.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page= Page: -	no

Drug as victim

Target	Modality	Activity
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	no
MRP2 205	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	no
MRP4 77	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	no
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=218 Page: 218.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=218 Page: 218.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	no
MATE1 135	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	yes
MATE2 96	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=219 Page: 219.0	yes
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=218 Page: 218.0	yes
OAT4 78	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=218 Page: 218.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 100	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=43 Page: 43.0
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf#page=43 Page: 43.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA008TMP	https://www.aablocks.com/goods/Goods/detail?id=AA008TMP
Aaron Chemicals	AR008UEH	http://www.aaronchem.com/1174018-99-5
BioSynth	J-690043	https://www.biosynth.com/en/products/all-products/products/J-690054.html
Chem Scene	CS-5391	http://www.chemscene.com/1174018-99-5.html
Chemspace	CSSB00025704714	https://chem-space.com/CSSB00025704714
DC Chemicals	DC10441	http://www.dcchemicals.com/product_show-Relebactam.html
Excenen	EX-A864	http://www.excenen.com/searchresultlist.php?id=1174018-99-5
Lab Network	LN01344109	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01344109
MedChem Express	HY-16752	https://www.medchemexpress.com/Relebactam.html
Selleck Chemicals	S0074	http://www.selleckchem.com/products/relebactam.html
Smolecule	S001942	http://www.smolecule.com/products/s001942
Smolecule	S541180	http://www.smolecule.com/products/s541180
Synblock Inc	SB16968	http://www.synblock.com/product/1174018-99-5.html
THE BioTek	bt-253515	https://www.thebiotek.com/product/inhibitors/bt-253515
THE BioTek	bt-280030	https://www.thebiotek.com/product/inhibitors/bt-280030
abcr GmbH	AB479629	http://www.abcr.com/shop/en/AB479629
eNovation Chemicals	D572888	https://www.enovationchem.com/ProductDetails.asp?ProductID=D572888
iChemical	EBD3724181	http://www.ichemical.com/products/1174018-99-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

Name

Type

Language

RELEBACTAM SODIUM

Common Name

English

RELEBACTAM SODIUM, (-)-

Common Name

English

MK-SODIUM SALT

Code

English

RELEBACTAM ANHYDROUS SODIUM

Common Name

English

SULFURIC ACID, MONO((1R,2S,5R)-7-OXO-2-((4-PIPERIDINYLAMINO)CARBONYL)-1,6-DIAZABICYCLO(3.2.1)OCT-6-YL) ESTER, SODIUM SALT (1:1)

Systematic Name

English

Code System Code Type Description

SMS_ID

100000179909